Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Equillium Inc

EQ ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$2.36

▲ +17.41%

Market Cap $149.64M · Vol 148.84K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$149.64M

Micro Cap

Div Yield

N/A

EPS Growth

+47.29%

YoY

RSI (14)

45.97

Momentum

Beta

1.75

vs Market

52W High

$3.54

33.33% below

52W Low

$0.76

212.09% above

Volume

148.84K

Avg 179.93K

P/B

3.33

Price-to-book

ROE

N/A

Return on equity

Free Float

83.85%

Public shares

Shariah Compliance8 STANDARDS

✗ Equillium Inc (EQ) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EQ pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+11.85%

-14.49%

-8.88%

+50.32%

YTD

+52.26%

+140.79%

+219.70%

-61.18%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-22,398,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-77.92% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.33
P/FCF	N/A
EPS Growth	+47.29%
Outstanding Shares	63.41M

Technical Indicators

50-Day SMA	$2.65
200-Day SMA	$1.91
RSI (14)	45.97
Beta	1.75
52-Week High	$3.54
52-Week Low	$0.76

Volume Today	148.84K
Avg Daily Volume (30D)	179.93K
Relative Volume	0.83x
Volatility (10D)	96.03
Volatility (30D)	82.81
Free Float	83.85%

Analyst Consensus

STRONG BUY

Current Price $2.36

Mean Target $8.60

52W Low$0.76 52W High$3.54

Current

Target

$0.76 $3.54

Current Analyst target

+264.41% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00LSL8C29

ISINUS29446K1060

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.